The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system
Open accessAbstract
Sporadic Parkinson's disease (PD) is most likely caused by a combination of environmental exposures and genetic susceptibilities, although there are rare monogenic forms of the disease. Mitochondrial impairment at complex I, oxidative stress, alpha-synuclein aggregation, and dysfunctional protein degradation, have been implicated in PD pathogenesis, but how they are related to each other is unclear. To further evaluated PD pathogenesis here, we used in vivo and in vitro models of chronic low-grade complex I inhibition with the pesticide rotenone. Chronic rotenone exposure in vivo caused oxidative modification of DJ-1, accumulation of alpha-synuclein, and proteasomal impairment. Interestingly, the effects become more regionally restricted such that systemic complex I inhibition eventually results in highly selective degeneration of the nigrostriatal pathway. DJ-1 modifications, alpha-synuclein accumulation, and proteasomal dysfunction were also seen in vitro and these effects could be prevented with alpha-tocopherol. Thus, chronic exposure to a pesticide and mitochondrial toxin brings into play three systems, DJ-1, alpha-synuclein, and the ubiquitin-proteasome system, and implies that mitochondrial dysfunction and oxidative stress link environmental and genetic forms of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“…et al., 2004), alterations in DJ-1, a protein associated with oxidative stress (Bonifati et al., 2003), accumulation and aggregation of a-synuclein (Polymeropoulos et al., 1997; Singleton et al., 2003), and defects in the ubiquitin– proteasome system (UPS) (Kitada et al., 1998; Leroy et al., 1998).”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“Genetic (monogenic) forms of PD have suggested roles for mitochondrial impairment (Valente et al., 2004), alterations in DJ-1, a protein associated with oxidative stress (Bonifati et al., 2003), accumulation and aggregation of a-synuclein (Polymeropoulos et al., 1997; Singleton et al., 2003), and defects in the ubiqui…”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Self-citationHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Self-citation
Cited by
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Mitochondrial Dynamics — Mitochondrial Fission and Fusion in Human Diseases
Archer, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215233 · Cited by 1,102
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
A highly reproducible rotenone model of Parkinson's disease
Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.016 · Cited by 795
Self-citationChin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 707
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Self-citationLRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Self-citationNeurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 505
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 474
The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases
Cannon, J. R., & Greenamyre, J. T. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr239 · Cited by 459
Self-citationMhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Pathological roles of α-synuclein in neurological disorders
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70213-7 · Cited by 357
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model
Sanders, L. H., & Timothy Greenamyre, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.003 · Cited by 345
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease
Büeler, H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.006 · Cited by 327
The 6-hydroxydopamine model: News from the past
Blandini, F., Armentero, M.-T., & Martignoni, E. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.015 · Cited by 311
Cicchetti, F., Drouin-Ouellet, J., & Gross, R. E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.005 · Cited by 311
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
Dodson, M. W., & Guo, M. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.04.010 · Cited by 278
Yadava, N., & Nicholls, D. G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0212-07.2007 · Cited by 272
“Thus, bioenergetic failure may initially be restricted to synaptic regions, interestingly correlating with the observation that neurodegeneration in the rat chronic rotenone model may be initiated at striatal dopaminergic nerve terminals (Betarbet et al., 2006).”
BackgroundInfluentialInden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04440.x · Cited by 260
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Choi, M. L., Chappard, A., Singh, B. P., Maclachlan, C., Rodrigues, M., Fedotova, E. I., Berezhnov, A. V., De, S., Peddie, C. J., Athauda, D., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01140-3 · Cited by 254
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199
“Despite the ubiquitous nature of the rotenone-induced Complex I inhibition, DA neurons were the most vulnerable to degeneration which mimics the loss of DA neurons in PD (Betarbet et al. 2000; Betarbet et al. 2006; Cannon et al. 2009).”
BackgroundMastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C.-A., Gearing, M., Trojanowski, J. Q., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.009 · Cited by 195
Self-citationPink1 regulates the oxidative phosphorylation machinery via mitochondrial fission
Liu, W., Acín-Peréz, R., Geghman, K. D., Manfredi, G., Lu, B., & Li, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107332108 · Cited by 190
Neurotoxins: Free radical mechanisms and melatonin protection
J. Reiter, R., C. Manchester, L., & Tan, D.-X. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246236 · Cited by 179
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Tapias, V., Hu, X., Luk, K. C., Sanders, L. H., Lee, V. M., & Greenamyre, J. T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2541-x · Cited by 126
Self-citationMembers, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Furthermore, ASYN protofibrils interact with intracellular organelles such as neurotransmitter vesicles or mitochondria, and lead to an uncontrolled release of DA and an impairment of mitochondrial function (Lotharius et al.”
BackgroundInfluentialProtection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116
Self-citationGut-brain and brain-gut axis in Parkinson’s disease models: effects of a uridine and fish oil diet
Perez-Pardo, P., Dodiya, H. B., Broersen, L. M., Douna, H., van Wijk, N., Lopes da Silva, S., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1294555 · Cited by 111
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript
Alemi, M., Prigione, A., Wong, A., Schoenfeld, R., DiMauro, S., Hirano, M., Taroni, F., & Cortopassi, G. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.09.014 · Cited by 50
Li, G., Kim, C., Kim, J., Yoon, H., Zhou, H., & Kim, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150024 · Cited by 42
Self-citationGlia-derived extracellular vesicles in parkinson’s disease.
Marchetti, B., Leggio, L., L’Episcopo, F., Vivarelli, S., Tirolo, C., Paternò, G., Giachino, C., Caniglia, S., Serapide, M. F., & Iraci, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061941 · Cited by 38
Metadata
- Authors
- Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J.-H., Lund, S., Na, H.-M., Taylor, G., Bence, N. F., Kopito, R., Seo, B. B., Yagi, T., Yagi, A., Klinefelter, G., Cookson, M. R., & Greenamyre, J. T.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 22
- Issue
- 2
- Pages
- 404-420
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2041831342
- Cited by
- 342
- References
- 79
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.